Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors. The study aims to evaluate the effectiveness of a gene-silencing drug, ALN-HSD, in reducing liver scarring and inflammation in patients with MASH, a chronic liver disease.
The intervention being tested is ALN-HSD, an investigational drug administered via subcutaneous injection. It is designed to improve liver function and reduce inflammation associated with MASH.
The study employs a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on February 9, 2023, and the latest update was submitted on June 23, 2025. These dates are crucial as they mark the timeline of the study’s progress and updates.
The outcome of this study could significantly impact Regeneron’s market position, as a successful treatment for MASH could lead to increased investor confidence and stock performance. The pharmaceutical industry is highly competitive, and advancements in gene-silencing treatments could set Regeneron apart from its competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.